Introducing the
Oncolux Theranostics System
Next Generation Introperative Therapy for Residual Cancer
Despite advances in surgical techniques and the use of adjuvant chemotherapy & radiotherapy, disease recurrence due to residual disease remains a significant problem in surgical oncology
Adjuvant intraoperative radiation therapy (IORT) given at the time of surgery has shown great benefit, especially in difficult, locally advanced tumor resection
Unfortunately, IORT carries toxic side effects, damage to healthy tissue, is cumbersome, and involves significant capital limiting its access to major cancer centers
We believe our disruptive theranostics system can target and apply photodynamic therapy (PDT) to treat residual disease and overcomes problems of IORT
Despite advances in surgical techniques and the use of adjuvant chemotherapy & radiotherapy, disease recurrence due to residual disease remains a significant problem in surgical oncology
Adjuvant intraoperative radiation therapy (IORT) given at the time of surgery has shown great benefit, especially in difficult, locally advanced tumor resection
Unfortunately, IORT carries toxic side effects, damage to healthy tissue, is cumbersome, and involves significant capital limiting its access to major cancer centers
We believe our disruptive theranostics system can target and apply photodynamic therapy (PDT) to treat residual disease and overcomes problems of IORT
